EFPIA Vision

The voice of the pharmaceutical industry in Europe;
Fostering health: a shared commitment to high quality and sustainable healthcare

 Read more
1
Innovative Medicines Initiative (IMI)

EFPIA contributes to IMI €223,7 million programme to tackle Antibiotic resistance

 Read More
2
European Stakeholder Model (ESM)

The stakeholder-governed solution proposed by EFPIA and its partners in the pharmaceutical supply chain is indeed likely to constitute ...

 Read More
3
Clinical Trials

Clinical Trials are tests in medical research needed for medicine development, and important to ensure the safety and quality of medicines

 Read more
4
1
2
3
4

News

16 Apr 2013
Nominations are now open for the Parliament Magazine's MEP Awards 2013
Nominations are now open for the Parliament Magazine's MEP Awards 2013  When and Where? Tuesday 25 June 2013 from 18.00, Concert Noble, Brussels  To...
5 Apr 2013
Invitation to the EUPATI 2013 Conference : A vision for 2020, Rome, 19 April 2013
The goal of this Conference is to look to the future: 2020 and three years beyond the end of the project, to how tools and knowledge provided through...
26 Mar 2013
Certificate in Healthcare Compliance Ethics & Regulation, 24 - 28 June 2013, Paris (France)
The Certificate in Healthcare Compliance Ethics & Regulation has been designed for Compliance Officers and Compliance Managers. It presents...

View all news

Press Release

23 Apr 2013
EFPIA endorses European Commission Memorandum of Understanding on the Sale of Counterfeit Goods
Brussels: 23.04.13  On 18th April 2013 the Commission released its first report evaluating the effectiveness of the Memorandum of Understanding (MoU...
19 Apr 2013
EFPIA and EuropaBio welcome European Commission Consensus Information Document on biosimilars in the European pharmaceutical environment
 Brussels, 19 April 2013 The European Federation of Pharmaceutical Industries & Associations (EFPIA), its specialised group the European...
18 Apr 2013
European Pharmaceutical Industry welcomes the compromise on the Priority Substances proposal
Brussels 18.04.13: EFPIA, AESGP & EGA, as the collective voice of the European pharmaceutical industry, welcome the compromise announced...

View all Press Release

Publications

18 Apr 2013
EFPIA & GS1: a shared vision for product identification in the context of the EU Directive on Falsified Medicines
18 Apr 2013
EFPIA European Pack Coding Guidelines
18 Apr 2013
European Medicines Verification System:Guidance for Manufacturers
Guidance for Manufacturers : What is required to be ready to connect to the EMVS?

View all Publications

Position Papers

9 Apr 2013
Disappointing decision by the Indian Supreme Court to deny a first patent to Novartis’ break through medicine Glivec
This week the Indian Supreme Court denied the patent application of Novartis for its breakthrough medicines Glivec even though it was rewarded a...
19 Nov 2012
EFPIA Position on Transparency of information on Clinical Trials included in the Proposed EU Database (Article 78 of the Proposal for a Regulation on Clinical Trials) - 10 December 2012
EFPIA recognises that patients, researchers or the public are interested in knowing what new treatments are tested in clinical trials or what the...
30 Oct 2012
EFPIA Position Clinical trial standards in developing and emerging countries in the context of the proposed EU Regulation on clinical trials on medicinal products for human use - 30 October 2012
Clinical trials are an essential part of medical research. No new medicine can be approved without its safety and efficacy first being proven in...

View all Position Papers

Latest entries

It’s DSM-5, not DSM-V: Why Little Differences Matter in the Mental Disorders Manual
23 May 2013
EFPIAs Director General Richard Bergström on the changing state of brain-related research and the significance of the new DSM-5.  The new edition of the Diagnostic and Statistical Manual of Mental Disorders was released last week, following weeks of controversy prior to its release. The change of...
Topics:
Development of Medicines Patients’ Access to Medicines Research & Innovation
Tags:
Access Medicines Development
The Impact of Bad Science
23 May 2013
EFPIAs Director General, Richard Bergström, outlines the need to handle scientific data with care. Medical science has allowed for advancements that improve patient health and well-being around the world – vaccines and cures are now available for a number of diseases once considered common killers...
Topics:
Development of Medicines Responsible Industry
Tags:
Clinical trials Medicines Development Patient Safety

Read more